ACON vs XTNT vs GKOS vs MDXG vs ATEC

For growth investors, Aclarion, Inc.

(ACON) is the stronger pick with 999999% revenue growth year-over-year, versus 20. 0% for MiMedx Group, Inc. (MDXG). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Alphatec Holdings, Inc.

is actually cheaper at 27. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -100. 0% for Aclarion, Inc. (ACON). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus ACON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 69β versus MiMedx Group, Inc. 's 1. 22β — meaning MDXG is approximately 77% more volatile than XTNT relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aclarion, Inc.

(ACON) is pulling ahead at 999999% versus 20. 0% for MiMedx Group, Inc. (MDXG). On earnings-per-share growth, the picture is similar: Aclarion, Inc. grew EPS 99. 8% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, ACON leads at 106. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MiMedx Group, Inc.

(MDXG) is the more profitable company, earning 11. 6% net margin versus -95. 5% for Aclarion, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -93. 1% for ACON. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Alphatec Holdings, Inc.

(ATEC) trades at 27. 1x forward P/E versus 295. 2x for MiMedx Group, Inc. — 268. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

In this comparison, ACON (100.

0% yield) pays a dividend. XTNT, GKOS, MDXG, ATEC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aclarion, Inc.

(ACON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), 100. 0% yield). Both have compounded well over 10 years (ACON: -100. 0%, MDXG: -48. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ACON pays a dividend while XTNT, GKOS, MDXG, ATEC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.